Literature DB >> 19944276

Diagnosis and management of infectious complications in critically ill patients with cancer.

Raghukumar Thirumala1, Madhusudanan Ramaswamy, Sanjay Chawla.   

Abstract

Cancer and its treatments lead to profound suppression of innate and acquired immune function. In this population, bacterial infections are common and may rapidly lead to overwhelming sepsis and death. Furthermore, infections caused by viral and fungal pathogens should be considered in patients who have specific immune defects. As cancer therapies have become more aggressive the risk for infection has increased and many patients require intensive care support. Despite improvements in long-term survival, infections remain a common complication of cancer therapy and accounts for the majority of chemotherapy-associated deaths. By understanding the host defense impairments and likely pathogens clinicians will be better able to guide diagnosis and management of this unique population.

Entities:  

Mesh:

Year:  2010        PMID: 19944276     DOI: 10.1016/j.ccc.2009.09.007

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  26 in total

Review 1.  Febrile neutropenia in hematologic malignancies.

Authors:  Michael K Keng; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

3.  [Mortality of hematology-oncology patients with neutropenia in intensivecare].

Authors:  I Suárez; B Böll; A Shimabukuro-Vornhagen; G Michels; M von Bergwelt-Baildon; M Kochanek
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-05-21       Impact factor: 0.840

4.  PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia.

Authors:  Matthew M Schaefers; Biyan Duan; Boaz Mizrahi; Roger Lu; Gally Reznor; Daniel S Kohane; Gregory P Priebe
Journal:  Vaccine       Date:  2018-10-09       Impact factor: 3.641

Review 5.  [Chronic critically ill patients from the perspective of hematologists/oncologists].

Authors:  T Staudinger; P Schellongowski
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-02-28       Impact factor: 0.840

Review 6.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

7.  Enhanced diagnostic yields of bacteremia and candidemia in blood specimens by PCR-electrospray ionization mass spectrometry.

Authors:  Thomas G Laffler; Lendell L Cummins; Colt M McClain; Criziel D Quinn; Michelle A Toro; Heather E Carolan; Donna M Toleno; Megan A Rounds; Mark W Eshoo; Charles W Stratton; Rangarajan Sampath; Lawrence B Blyn; David J Ecker; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

8.  Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Authors:  Kendra N Iskander; Marcin F Osuchowski; Deborah J Stearns-Kurosawa; Shinichiro Kurosawa; David Stepien; Catherine Valentine; Daniel G Remick
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

9.  Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia.

Authors:  Akinobu Kamei; Weihui Wu; David C Traficante; Andrew Y Koh; Nico Van Rooijen; Gerald B Pier; Gregory P Priebe
Journal:  J Infect Dis       Date:  2012-10-24       Impact factor: 5.226

10.  [Neutropenia and sepsis].

Authors:  M Kochanek; B Böll; M Hallek; M von Bergwelt-Baildon
Journal:  Internist (Berl)       Date:  2013-09       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.